Mesalazine for the treatment of inflammatory bowel disease

Bibliography

• Baron JH, Connel AM, Lennard-Jones JE, et al. Sulphasalzine and salicylazosulphadimidine in ulcerative colitis. Lancet 1962;i:1094-6
   Google Scholar
• Misiewicz J, Lennard-Jones JE, Connell AM, et al. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1965;i:185-8
   Google Scholar
• Azad Kahn AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977;ii:892-5
   Google Scholar
• Van Hees PAM, Bakker JH, Van Tongeren JHM. Effect of sulphapyridine, 5-aminosalicylic acid and placebo in patients with idiopathic proctitis: study to determine the active therapeutic moiety of sulphasalazine. Gut 1980;21:632-5
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg Tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology 2009;137:1934-43
   PubMedGoogle Scholar
• Ito H, Iida M, Matsumoto T, et al. Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study. Inflamm Bowel Dis 2010;16:1567-74
   PubMed Web of Science ®Google Scholar
• Scherl EJ, Pruitt R, Gordon GL, et al. Safety and efficacy of a new 3.3 g b.i.d. Tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2009;104:1452-9
   PubMed Web of Science ®Google Scholar
• Prantera C, Viscido A, Biancone L, et al. A new oral delivery system for 5-ASA: preliminary clinical findings for MMX. Inflamm Bowel Dis 2005;11:421-7
   PubMed Web of Science ®Google Scholar
• D'haens G, Hommes D, Engel L, et al. Once daily MMX mesalazine for the treatment of mild to moderate ulcerative colitis: a phase II dose ranging study. Aliment Pharmacol Ther 2006;24:1087-97
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Kamm MA, Boddu P, et al. Effects of once- twice daily MMX mesalazine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007;5:95-102
   PubMed Web of Science ®Google Scholar
• Kamm MA, Sandborn WJ, Gassull M, et al. Once daily, high concentration MMX mesalazine or the induction of remission in active ulcerative colitis. Gastroenterology 2007;132:66-75
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX multi matrix system mesalazine for the induction of remission in patients with mild to moderate ulcerative colitis: a combined analysis of two randomized, double blind, placebo controlled trials. Aliment Pharmacol Ther 2007;26:205-15
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Kamm MA, Sandborn WJ, et al. MMX mesalamine for the induction of remission of mild-to moderate active ulcerative colitis: efficacy and tolerability in specific patients subpopulation. Aliment Pharmacol Ther 2008;27:1094-102
   PubMedGoogle Scholar
• Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Effect of extended MMX mesalamine therapy for acute, mild to moderate ulcerative colitis. Inflamm Bowel Dis 2009;15:1-8
   PubMed Web of Science ®Google Scholar
• Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD000543; Review
   PubMed Web of Science ®Google Scholar
• Khan N, Abbas AM, Bazzano LA, et al. Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system. Aliment Pharmacol Ther 2012;36(8):755-64
   PubMed Web of Science ®Google Scholar
• Feagan BG, MacDonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD000544; Review
   PubMedGoogle Scholar
• Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010;1):CD004115; Review
   Google Scholar
• Ford AC, Khan KJ, Achkar JP. Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2012;107(2):167-76; author reply 177
   PubMed Web of Science ®Google Scholar
• Marshall JK, Thabane M, Steinhart AH, et al. Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;11:CD004118; Review
   PubMedGoogle Scholar
• Meucci G, Fasoli R, Saibeni S, et al. IG-IBD. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis 2012;18(6):1006-10
   PubMed Web of Science ®Google Scholar
• Loftus E.V, Kane S, Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2004;19:179-89
   PubMed Web of Science ®Google Scholar
• Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35
   PubMed Web of Science ®Google Scholar
• Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol 2005;100:1345-53
   PubMed Web of Science ®Google Scholar
• Nguyen GC, Gulamhusein A, Bernstein CN. 5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol 2012;107(9):1298-304
   PubMed Web of Science ®Google Scholar
• Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathological clinical entity. JAMA 1932;99:1323-9
   Google Scholar
• Loftus EV Jr, Silverstein D, Sandborn WJ, et al. Crohn's disease in Olmsted County, Minnesota 1940-1993: incidence, prevalence and survival. Gastroenterology 1999;116:1161-8
   Web of Science ®Google Scholar
• Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther 2006;24(Suppl 1):2-9
   PubMed Web of Science ®Google Scholar
• Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of post-operative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000;118:264-73
   PubMed Web of Science ®Google Scholar
• Steinhart AH, Hemphill D, Greenberg GR. Sulfasalazine and mesalazine for the maintenance therapy of Crohn's disease: a meta-analysis. Am J Gastroenterol 1994;89:2116-24
   PubMedGoogle Scholar
• Messori A, Brignola C, Trallori G, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol 1994;89:692-8
   PubMedGoogle Scholar
• Mahida YR, Jewell DP. Slow release 5-aminosalicylic acid (Pentasa) for the treatment of active Crohn's disease. Digestion 1990;45:88-92
   PubMed Web of Science ®Google Scholar
• Tremaine WJ, Schroeder KW, Jarrison JM, et al. A randomized, double blind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994;19:278-82
   PubMed Web of Science ®Google Scholar
• Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study (NCCDS): results of drug treatment. Gastroenterology 1979;77:847-69
   PubMed Web of Science ®Google Scholar
• Prantera C, Cottone M, Pallone F, et al. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial. Gastroenterology 1999;116:521-6
   PubMedGoogle Scholar
• Malchow M, Ewe K, Brandes JW, et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-66
   PubMed Web of Science ®Google Scholar
• Hanauer S, Stromberg U. Oral Pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379-88
   PubMed Web of Science ®Google Scholar
• Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst Rev 2010;12):CD008870
   Google Scholar
• Rasmussen SN, Lauritsen K, Tage-Jensen U, et al. 5-Aminosalicylic acid in the treatment of Crohn's disease: a 16-week double-blind, placebo-controlled, multicentre study with Pentasa. Scand J Gastroenterol 1987;22:877-83
   PubMed Web of Science ®Google Scholar
• Singleton JW, Hanauer SB, Gitnick GL, et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Gastroenterology 1993;104:1293-301
   PubMed Web of Science ®Google Scholar
• Ford AC, Kane SV, Khan KJ, et al. Efficacy of 5-Aminosalicylates in Crohn's disease: systematic review and Meta-analysis. Am J Gastroenterol 2011;106:617-29
   PubMed Web of Science ®Google Scholar
• Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 2010;4:28-62
   Google Scholar
• Tromm A, Bunganič I, Tomsová E, et al. International Budenofalk Study Group. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology 2011;140(2):425-34
   PubMed Web of Science ®Google Scholar
• Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2005;CD003715
   Google Scholar
• Modigliani R, Colombel JF, Dupas JL, et al. Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1996;110:688-93
   PubMedGoogle Scholar
• Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984;25:665-72
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990;99:956-63
   PubMed Web of Science ®Google Scholar
• Renna S, Cammà C, Modesto I, et al. Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 2008;135(5):1500-9
   PubMed Web of Science ®Google Scholar
• Cottone M, Orlando A, Viscido A, et al. Review article: prevention of postsurgical relapse and recurrence in Crohn's disease. Aliment Pharmacol Ther 2003;17(Suppl 2):38-42
   PubMedGoogle Scholar
• Gordon M, Naidoo K, Thomas AG, et al. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2011;1:CD008414
   Google Scholar
• Ardizzone S, Maconi G, Sampietro G, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 2004;127(3):730-40
   PubMed Web of Science ®Google Scholar
• Hanauer S, Korelitz B, Rutgeerts P, et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004;127(3):723-9
   PubMed Web of Science ®Google Scholar
• Camma C, Viscido A, Latella G, et al. Mesalamine in the prevention of clinical and endoscopic postoperative recurrence of Crohn's disease: a meta-analysis [abstract]. Dig Liver Dis 2002;34(Suppl 1):A86
   PubMedGoogle Scholar
• Gao X, Zhang FB, Ding L, et al. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients. Eur J Gastroenterol Hepatol 2012;24(8):958-64
   PubMedGoogle Scholar